Wo steht die Pharmakogenetik nach 30 Jahren Forschung?

Literatur
1 Brauch H, Schroth W, Goetz MP et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2012; 31: 176-180
2 Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012; 44: 116-126
3 Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137
4 Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis Ctreatment-induced viral clearance. Nature 2009; 461: 399-401
5 Klein TE, Altmann RB et al. Estimation of the Warfarin dose with clinical and pharmacogenetic data. The International Warfarin Pharmacogenetics Consortium. N Engl J Med 2009; 360: 753-764
6 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205
7 McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143
8 Rae JM, Drury S, Hayes DF et al. ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460
9 Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-451
10 Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857